Our success as a BioPharma leader has been fueled by our pioneering approach to bolster our early- and mid-stage research and pipeline through a series of acquisitions, collaborations, alliances and agreements. They have helped balance our portfolio and build clusters of expertise in key therapeutic areas where there is great unmet medical need. We acquired skilled people, great science, potential products and in some areas, marketed products. And we’ve positioned ourselves as a strong partner in biotech circles by demonstrating our ability to nurture innovation, assets and talent.

Adnexus Therapeutics

Amylin Pharmaceuticals

Biocon Bristol-Myers Squibb Research Center (BBRC)

ZymoGenetics